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Retrospective studies of administrative databases have led to 
highly variable estimates of the incidence and natural history 
of drug-induced liver injury (DILI) and the agents implicated. 
In contrast, prospective multicenter registry studies allow for 
more accurate phenotyping of individual patients with DILI, 
as well as for collection of biological samples for mechanistic 
studies. In addition to improved diagnostic and prognostic 
biomarkers, standardized causality assessment tools are 
needed, as well as population-based studies that represent the 
full spectrum of disease severity. This would facilitate further 
research into the pathogenesis of DILI, leading ultimately to 
the prevention of this condition.
The increased use of prescription medications has been associ-
ated with improvement in the general health, well being, and 
longevity of millions of people in the United States. However, 
a concomitant increase in the incidence of multiple serious 
adverse drug reactions (ADRs) has also been reported. Although 
drug-induced liver injury (DILI) is relatively uncommon (the 
estimated incidence related to the use of individual drugs 
ranges from 1 in 10,000 to 1 in 1,000,000 patient-years), DILI 
is the most common reason for drugs in development being 
denied regulatory approval and for others being withdrawn.1 
Furthermore, the morbidity and mortality from DILI are sub-
stantial, with nearly 10% of the patients who develop jaundice 
from severe acute hepatocellular liver injury dying or requiring 
liver transplantation.2 Therefore, additional studies of the risk 
factors and mechanisms of DILI are urgently needed to allow 
otherwise effective drugs to be safely administered to the grow-
ing population of aging individuals.
Recognition and diagnosis of dili
The incidence of DILI is not well known, in part because of the 
lack of standardized and universally accepted diagnostic criteria. 
Given that DILI accounts for <1% of American patients present-
ing with acute hepatitis and/or jaundice, clinicians must first 
exclude other more common etiologies of liver disease such as 
viral hepatitis (i.e., A, B, C), alcohol, pancreaticobiliary disease, 
hepatic ischemia, and autoimmune hepatitis.3,4 Also, DILI due to 
a particular drug can lead to differing phenotypes in  individual 
patients and can mimic nearly all forms of acute and chronic 
liver disease. Finally, most cases of DILI are not related to the 
dose, route, or duration of treatment with the suspect medi-
cation and are not restricted to any readily identifiable group 
of high-risk patients. These challenges, coupled with the lack 
of a confirmatory laboratory biomarker, make DILI largely a 
 diagnosis of exclusion based on “circumstantial evidence.”
Several clinical features are commonly sought in attempt-
ing to evaluate the role of a medication in patients with 
otherwise unexplained acute and/or chronic liver disease 
(Table 1).5 Unfortunately, most DILI patients do not have 
 readily  recognizable hypersensitivity features such as rash or 
eosinophilia at presentation. In addition, diagnostic  challenges 
arise if a patient is taking multiple medications, herbal or dietary 
 supplements with multiple ingredients, or a newly approved drug 
without an established signature of hepatotoxicity.6 Patients with 
underlying liver disease who may be more susceptible to adverse 
outcomes can pose formidable diagnostic challenges. Finally, not 
all patients improve with dechallenge, and  rechallenge is rarely, if 
ever, knowingly performed.7 Several causality assessment instru-
ments have been used to help standardize the approach to DILI 
diagnosis.6 However, the currently available instruments, includ-
ing expert opinion, have substantial inter- and intraindividual 
variability.8 Therefore, improved, evidence-based  causality 
assessment methods and objective laboratory biomarkers of 
DILI are urgently needed.
RetRospective studies of dili
Several retrospective studies of DILI in the United States 
have described its incidence, the suspect medications, and 
patient outcomes.4,9 Many of these studies relied on a search 
of avai lable medical records or administrative databases for 
either keywords or ICD-9 codes (from the International 
Classification of Diseases, 9th revision) associated with 
DILI.4,10 However, most of these ICD-9 codes have a low 
specificity (1–5%), and the sensitivity of these approaches is 
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limited because of the lack of a gold standard for diagnosis. 
The estimated incidence of DILI in these studies has been 
highly variable because of differences in case definition, 
coding accuracy, and the extent to which competing eti-
ologies were excluded (i.e., 0.024% in a health maintenance 
organization population vs. 1% in hospitalized patients).11,12 
Furthermore, the true incidence of DILI is probably underes-
timated, whereas its severity is probably overestimated from 
referral center studies given that the majority of DILI cases in 
the general population present as asymptomatic outpatients.13 
Future studies of DILI epidemio logy, merging laboratory, 
medication, and health-care claims databases and using the 
more robust and specific ICD-10 diagnostic coding, may prove 
informative for hypothesis generation regarding putative risk 
factors. However, pharmaco epidemiological inferences from 
retrospective studies of a rare and difficult-to-diagnose ADR 
like DILI should be interpreted with caution.
postmaRketing suRveillance stRategies
The US Food and Drug Administration has tracked a multi-
tude of ADRs for many years through the MedWatch volun-
tary reporting system. However, important diagnostic data 
are frequently missing or incomplete, and the ability to obtain 
follow-up information is limited.14 Furthermore, it is estimated 
that <10% of all ADRs are reported to regulatory authorities, 
because of the reluctance of clinicians to report new ADRs. (In 
support of this, a recent prospective study demonstrated that 
the true incidence of DILI in the general population of France 
was nearly 16-fold higher than that reported to regulatory 
 authorities.13) Therefore, government registries have limited 
ability to accurately track the incidence, etiologies, and outcomes 
of DILI in the general population. Nonetheless, data mining of 
these databases can help to detect hepatotoxicity signals from 
 existing products on the market and also generate hypotheses 
for risk factors.15
pRospective studies
the dili network
The DILI Network (DILIN) was established by the National 
Institutes of Health in 2003 to improve our understanding of 
the risk factors, natural history, and biological basis of DILI. 
Eight clinical sites along with a data-coordinating center provide 
the infrastructure to enroll pediatric and adult patients with liver 
injury that meets minimal laboratory criteria and is suspected to 
be due to any drug or herbal product taken within the 6 months 
before the onset of the injury.16 Patients with known fatty liver 
disease, chronic hepatitis B or C, or HIV infection are encour-
aged to participate.
At the baseline study visit, a detailed medical history is 
obtained, and a physical examination is carried out to exclude 
competing causes of liver injury (Table 2). In addition, blood, 
urine, peripheral lymphocytes, and DNA samples are  collected 
for mechanistic studies. Available liver biopsy samples are 
reviewed by an expert hepatopathologist to create a library of 
diagnostic and prognostic histopathological features of well-
characterized cases of DILI. All subjects with laboratory or 
radiological evidence of ongoing liver injury 6 months after the 
onset of DILI are followed so as to determine the outcome at 
2 years. The DILIN prospective study also retains contact with 
patients for up to 20 years after enrollment, for participation in 
future mechanistic studies.
In order to promote awareness of the study and to facilitate 
recruitment, brochures and e-mails are sent to local physicians 
and related information is published in professional journals 
and posted at national meetings. A recent report of the first 
300 patients enrolled in the DILIN prospective study showed 
that 60% were female and 70% were Caucasian; the mean age 
was 48 years (range: 2–81 years).17 The mean serum alanine 
aminotransferase level was 788 IU/l at the onset of DILI, with a 
mean total bilirubin level of 11.4 mg/dl. More than 50% of the 
subjects required hospitalization, and nearly 60% underwent 
liver biopsies.
Causality is determined by consensus expert opinion of three 
experienced hepatologists who independently review all the 
available clinical, laboratory, and diagnostic data as well as a 
clinical narrative. The majority of the first 300 DILIN patients 
had high causality scores, with 32% being definite, 41% very 
likely, and 14% probable. However, there were nine patients 
(3%) with other more likely causes of liver injury, including 
unsuspected acute hepatitis C virus infection. The median 
duration of medication use was 42 days, with antibiotics (45%) 
and central nervous system–acting drugs (15%) being the most 
commonly implicated drugs. A single drug was implicated in 
DILI in 73% of the patients, whereas more than a single drug 
was suspected in 18% and a variety of herbal products in 9%. 
The most commonly reported suspect drugs were  amoxicillin/
clavulanate, followed by nitrofurantoin, isoniazid, and 
 trimethoprim-sulfamethoxazole.
table 1 diagnostic criteria for idiosyncratic drug-induced liver 
injury
Criterion Comment
time to onset Variable range with many drugs but 
usually <12 months
Course of liver injury after drug 
cessation
Dechallenge is problematic in ALF 
patients and in those who develop 
chronic injury
Risk factor(s) for hepatotoxicity Few bona fide clinical risk factors 
have been established
Concomitant hepatotoxic drugs Difficult to exclude when multiple 
drugs or herbals are coadministered
Exclusion of competing causes Differ for hepatocellular and 
cholestatic/mixed
prior reports of hepatotoxicity problematic with newly approved 
drugs and herbal products
Rechallenge Rarely done and shows variable 
results
Liver histology DILI can mimic nearly all known 
forms of acute and chronic liver injury
Objective and confirmatory 
laboratory test
Validated diagnostic biomarkers not 
yet established
ALF, acute liver failure; DILI, drug-induced liver injury.
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the acute liver failure study group
The Acute Liver Failure Study Group (ALFSG) is a consortium 
of academic centers funded by the National Institutes of Health 
to study the etiologies and outcomes of acute liver  failure (ALF) 
in the United States. ALF is a dramatic and potentially life-
 threatening clinical syndrome defined by the onset of coagulopa-
thy (international normalized ratio >1.5) and changes in mental 
status within 8–26 weeks of the onset of the illness, with an esti-
mated annual incidence of only 3,000 cases/year in the United 
States.18 All enrolled ALFSG patients have extensive clinical data 
and biological samples collected during their  hospital stay. A 
review of the first 1,033 adult ALF patients enrolled between 1998 
and 2007 demonstrated that acetaminophen overdose accounted 
for 45% of the cases and idiosyncratic DILI for 12%.5 Three-week 
spontaneous survival was 64% in patients with acetaminophen 
overdose but only 26% in those with severe idiosyncratic DILI.
The mean age of the 133 ALF patients with idiosyncratic DILI 
was 44 years, and 71% of them were female.19 The median value 
of serum alanine aminotransferase at the time the patient pre-
sented with the condition was 574 IU/l, and the median bilirubin 
value was 21 mg/dl. The most frequently implicated agents were 
antituberculosis drugs (18%), sulfa compounds (9%), and pheny-
toin (7%). Causality assessment by expert opinion classified 81% 
as highly likely and 15% as probable.19 Research challenges iden-
tified in this study include the inability to obtain a reliable medi-
cation history from the patient, the lack of improvement with 
dechallenge, and the absence of any unique diagnostic features in 
many of the DILI patients as compared with subjects with inde-
terminate ALF. However, all the enrolled patients have now been 
followed up for 2 years in order to determine long-term outcomes 
and for enrollment in additional mechanistic studies.
united network of organ sharing database
The indications and outcomes of all patients in the United 
States undergoing solid organ transplantation are tracked by 
the United Network of Organ Sharing (UNOS). A recent review 
of 141 adults with ALF due to DILI who underwent liver trans-
plantation between 1992 and 2001 showed a preponderance of 
women (76%).20 The most commonly implicated drugs were 
isoniazid (17%), propylthiouracil (9%), phenytoin (7%), and 
 valproate (7%). These findings, and those of the ALFSG, suggest 
that several classes of commonly used drugs (such as antibiotics 
and anticonvulsants) are the most frequent causes of severe DILI 
in the United States. However, the limitations of the UNOS data-
base include a lack of information regarding the indication for 
which the suspect medication was prescribed, how a diagnosis 
was established, and the duration of use of the medication.
futuRe studies
Continued enrollment of patients into prospective registry studies 
such as the DILIN initiative and others should help to improve 
our understanding of the incidence and etiologies of  idiosyncratic 
table 2 visit schedule in the dilin prospective study
item Baseline visit 6-month study visit 12- and 24-month study visits
Eligible patients All with suspected DILI All with suspected DILI Chronic DILI patients onlya
Demographics X
pharmacy use X
Medication compliance X
Family history X
Lifetime use of suspect medication X
Diagnostic laboratory testsb X
HCV/HBV follow-up labsc X X
Concomitant medication and herbal 
product use
X X X
Medical history X X X
Alcohol use and smoking X X X
physical examination X X X
symptom score X X X
Quality-of-life survey X X X
standard laboratory tests X X X
Research blood sample X X X
Research urine sample X X X
Liver imaging X X X
Anti-smAb, anti-smooth muscle antibody; CMV, cytomegalovirus; DILI, drug-induced liver injury; DILIN, DILI Network; EBV, Epstein–Barr virus; HBV, hepatitis B virus; 
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; IgM, immunoglobulin M.
aChronic DILI: evidence of persistent laboratory, radiologic, or pathologic abnormalities 6 months after onset of DILI. bAll subjects must have testing for anti-HAV (IgM), HBsAg, 
anti-HBc (IgM), anti-HCV, HCV RNA, ANA, anti-smAb, and ceruloplasmin if age <50, AMA if mixed/cholestatic DILI, anti-CMV (IgM), or CMV-DNA by pCR, and EBV serologies or 
monospot test. cOnly in patients with known chronic HCV/HBV before onset of DILI.
Adapted from ref. 16.
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DILI. However, additional population-based  studies are also 
needed to define the full spectrum of severity of DILI in the gen-
eral population. True prospective studies that track a large group 
of patients receiving a drug such as isoniazid, from the time of 
 initial exposure until the onset of liver injury, would provide 
important information regarding clinical, environmental, and 
dietary risk factors. However, prospective monitoring of a cohort 
of several thousand treated patients for an ADR that occurs in 
<1% of exposed individuals requires tremendous resources.
The value of collecting biological samples for mechanis-
tic  studies from individual patients with bona fide DILI was 
recently demonstrated in a case–control study of patients with 
 flucloxacillin-related cholestasis.21 In that study, an 80-fold 
increased risk of DILI was attributable to a single-nucleotide poly-
morphism in the HLA-B*5701 locus, which was confirmed in a 
validation cohort. This striking proof-of-concept study demon-
strates the potential value of modern genomics,  transcriptomics, 
and proteomics in unraveling the mechanism of rare ADRs such 
as DILI. The development of prospective DILI registries in coun-
tries that utilize similar recruitment, eligibility, and  causality 
assessment methods (e.g., Spain, Japan, and Korea) will prove 
invaluable for validating future diagnostic and prognostic biomar-
kers of DILI.22 It is hoped that these efforts will ultimately pro-
vide clinicians with the tools and knowledge to better follow the 
Hippocratic oath of “Do No Harm” by maximizing efficacy and 
minimizing the incidence of unintended ADRs such as DILI.
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